BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mínguez B, Lachenmayer A. Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers. 2011;31:181-190. [PMID: 22045404 DOI: 10.3233/dma-2011-0841] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
Number Citing Articles
1 Bibi F, Ali I, Naseer MI, Ali Mohamoud HS, Yasir M, Alvi SA, Jiman-Fatani AA, Sawan A, Azhar EI. Detection of genetic alterations in gastric cancer patients from Saudi Arabia using comparative genomic hybridization (CGH). PLoS One 2018;13:e0202576. [PMID: 30212456 DOI: 10.1371/journal.pone.0202576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Cavedon E, Barollo S, Bertazza L, Pennelli G, Galuppini F, Watutantrige-Fernando S, Censi S, Iacobone M, Benna C, Vianello F, Zovato S, Nacamulli D, Mian C. Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. Int J Endocrinol 2017;2017:4915736. [PMID: 28676824 DOI: 10.1155/2017/4915736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
3 Huang G, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, Wieck LR, Li A, Okorodudu AO, Petersen JR, Abdulla NE, Duchini A, Cicalese L, Rastellini C, Hu PC, Dong J. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014;52:899-909. [PMID: 24406287 DOI: 10.1515/cclm-2013-0885] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
4 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003-12021. [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
5 Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N, Xie Y. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One. 2014;9:e109347. [PMID: 25275448 DOI: 10.1371/journal.pone.0109347] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
6 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
7 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014;273:30-50. [PMID: 25247563 DOI: 10.1148/radiol.14132362] [Cited by in Crossref: 256] [Cited by in F6Publishing: 188] [Article Influence: 42.7] [Reference Citation Analysis]
8 Yu L, Ding GF, He C, Sun L, Jiang Y, Zhu L. MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PLoS One 2014;9:e91661. [PMID: 24675898 DOI: 10.1371/journal.pone.0091661] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
9 Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014;9:e95485. [PMID: 24830459 DOI: 10.1371/journal.pone.0095485] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
10 Li J, Fang L, Yu W, Wang Y. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif. Oncol Lett 2015;9:1971-5. [PMID: 25789078 DOI: 10.3892/ol.2015.2973] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
11 Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, Kiesslich T, Stojakovic T, Samonigg H, Kornprat P, Lackner C, Haybaeck J, Pichler M. Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma. Br J Cancer 2013;108:1830-7. [PMID: 23591196 DOI: 10.1038/bjc.2013.165] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
12 Liu D, Hu X, Zhou H, Shi G, Wu J. Identification of Aberrantly Expressed miRNAs in Gastric Cancer. Gastroenterol Res Pract. 2014;2014:473817. [PMID: 24982669 DOI: 10.1155/2014/473817] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
13 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
14 Zahid KR, Yao S, Khan ARR, Raza U, Gou D. mTOR/HDAC1 Crosstalk Mediated Suppression of ADH1A and ALDH2 Links Alcohol Metabolism to Hepatocellular Carcinoma Onset and Progression in silico. Front Oncol 2019;9:1000. [PMID: 31637215 DOI: 10.3389/fonc.2019.01000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Ammendola M, Sacco R, Sammarco G, Piardi T, Zuccalà V, Patruno R, Zullo A, Zizzo N, Nardo B, Marech I, Crovace A, Gadaleta CD, Pessaux P, Ranieri G. Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. Onco Targets Ther 2016;9:4465-71. [PMID: 27499640 DOI: 10.2147/OTT.S105368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
16 Kanda M, Murotani K, Sugimoto H, Miwa T, Umeda S, Suenaga M, Hayashi M, Hattori N, Tanaka C, Kobayashi D, Yamada S, Fujiwara M, Kodera Y. An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma. Oncotarget 2017;8:71070-9. [PMID: 29050343 DOI: 10.18632/oncotarget.20369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7:139-149. [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
18 Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G. Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. Oncol Lett. 2015;9:1201-1206. [PMID: 25663882 DOI: 10.3892/ol.2014.2823] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
19 El-Halawany MS, Ismail HM, Zeeneldin AA, Elfiky A, Tantawy M, Kobaisi MH, Hamed I, Abdel Wahab AH. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int 2015;2015:649750. [PMID: 25811030 DOI: 10.1155/2015/649750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
20 Bibi F, Naseer MI, Alvi SA, Yasir M, Jiman-Fatani AA, Sawan A, Abuzenadah AM, Al-Qahtani MH, Azhar EI. microRNA analysis of gastric cancer patients from Saudi Arabian population. BMC Genomics. 2016;17:751. [PMID: 27766962 DOI: 10.1186/s12864-016-3090-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
21 Chen G, Lu L, Liu C, Shan L, Yuan D. MicroRNA-377 suppresses cell proliferation and invasion by inhibiting TIAM1 expression in hepatocellular carcinoma. PLoS One 2015;10:e0117714. [PMID: 25739101 DOI: 10.1371/journal.pone.0117714] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
22 Kuo CC, Shih YL, Su HY, Yan MD, Hsieh CB, Liu CY, Huang WT, Yu MH, Lin YW. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma. World J Gastroenterol 2015;21:3960-9. [PMID: 25852282 DOI: 10.3748/wjg.v21.i13.3960] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
23 Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167-1178. [PMID: 24039437 DOI: 10.2147/ott.s36161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
24 Zeng Z, Cao Z, Tang Y. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. Oncol Lett 2020;20:231. [PMID: 32968453 DOI: 10.3892/ol.2020.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 González R, De la Rosa ÁJ, Rufini A, Rodríguez-Hernández MA, Navarro-Villarán E, Marchal T, Pereira S, De la Mata M, Müller-Schilling M, Pascasio-Acevedo JM, Ferrer-Ríos MT, Gómez-Bravo MA, Padillo FJ, Muntané J. Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS One 2017;12:e0174326. [PMID: 28350813 DOI: 10.1371/journal.pone.0174326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 Zahid KR, Han S, Zhou F, Raza U. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death. Cell Oncol (Dordr) 2019;42:55-66. [PMID: 30238408 DOI: 10.1007/s13402-018-0407-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Xu YX, Wang YB, Tan YL, Xi C, Xu XZ. Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis. Medicine (Baltimore). 2019;98:e14027. [PMID: 30633195 DOI: 10.1097/md.0000000000014027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Hammoud GM, Ibdah JA. Are we getting closer to understanding intratumor heterogeneity in hepatocellular carcinoma?Hepatobiliary Surg Nutr. 2016;5:188-190. [PMID: 27115014 DOI: 10.3978/j.issn.2304-3881.2016.01.06] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
29 Xu Y, Wang B, Zhang F, Wang A, Du X, Hu P, Zhu Y, Fang Z. Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition. Onco Targets Ther. 2017;10:1191-1198. [PMID: 28280353 DOI: 10.2147/ott.s127100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
30 Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA, Ahmed N. Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics 2013;10:6. [PMID: 23724895 DOI: 10.1186/1559-0275-10-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
31 Han F, Liu W, Jiang X, Shi X, Yin L, Ao L, Cui Z, Li Y, Huang C, Cao J, Liu J. SOX30, a novel epigenetic silenced tumor suppressor, promotes tumor cell apoptosis by transcriptional activating p53 in lung cancer. Oncogene 2015;34:4391-402. [PMID: 25435374 DOI: 10.1038/onc.2014.370] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
32 Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget 2015;6:37200-15. [PMID: 26468984 DOI: 10.18632/oncotarget.5808] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
33 Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J, Ren T, Gutkind JS. MicroRNA-7–regulated TLR9 signaling–enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. MBoC 2013;24:42-55. [DOI: 10.1091/mbc.e12-07-0519] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
34 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Reference Citation Analysis]
35 Shen J, Wang S, Zhang YJ, Kappil MA, Chen Wu H, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH. Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma. Epigenetics. 2012;7:1230-1237. [PMID: 22976466 DOI: 10.4161/epi.22140] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
36 Zhu R, Guo W, Xu XJ, Zhu L. An Integrating Immune-Related Signature to Improve Prognosis of Hepatocellular Carcinoma. Comput Math Methods Med 2020;2020:8872329. [PMID: 33204302 DOI: 10.1155/2020/8872329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cheng J, Krausz KW, Tanaka N, Gonzalez FJ. Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. Toxicol Sci 2012;129:456-68. [PMID: 22790967 DOI: 10.1093/toxsci/kfs211] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
38 Wang Y, Luo Y, Li C, Zhang X, Pi C, Yu L, Wang S, Zhong Z. Optimized formulation of multivesicular liposomes loaded with oleanolic acid enhanced anticancer effect in vitro. Drug Des Devel Ther 2017;11:955-68. [PMID: 28392677 DOI: 10.2147/DDDT.S128795] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]